Projects per year
Personal profile
Research interests
Dr. David Claxton has longstanding interests in leukemia biology and therapeutics. Leukemia molecular genetics and diagnostics are ongoing interests. Acute myeloid leukemia and related disorders are his principal foci. Leukemia therapeutics are particular interests, including drug development and clinical studies, blood and marrow transplantation, and clinical supportive care. He has a laboratory which has banked many samples of human leukemias and lymphomas. These are viably cryopreserved, used in studies and available to collaborators.
Fingerprint
Dive into the research topics where David Claxton is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 16 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
- 1 Active
-
Targeted Sphingolipid Metabolism for Treatment of AML
Claxton, D., Kester, M., Loughran, T. P., Kester, M., Loughran, T. P., CABOT, M., Kester, M., Fox, T., LIAO, J., Kester, M., Wang, H., Amin, S., Kester, M., Kester, M., Wang, H., Kester, M., Loughran, T. P., CABOT, M., Kester, M., Kester, M., Fox, T., Kester, M., Kester, M., LIAO, J., Loughran, T. P., Kester, M., Loughran, T. P., CABOT, M., Kester, M., Kester, M., Fox, T., CLAXTON, D., LIAO, J., Loughran, T. P., JANES, K., Conaway, M., Kester, M., Loughran, T. P., Wang, H. G., Cabot, M. C., AMIN, S. G. & Fox, T. E.
9/10/13 → 5/31/21
Project: Research project
Research output
-
AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy
Yan, B., Claxton, D., Huang, S. & Qiu, Y., Jul 2020, In: Experimental Hematology. 87, p. 13-19 7 p.Research output: Contribution to journal › Article › peer-review
-
A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia
Zheng, H., Mineishi, S., Claxton, D., Zhu, J., Zhao, C., Jia, B., Ehmann, W. C., Rybka, W. B., Naik, S., Songdej, N., Drabick, J. J. & Hohl, R. J., 2020, (Accepted/In press) In: American Journal of Hematology.Research output: Contribution to journal › Letter › peer-review
Open Access -
Ceramide analogue SACLAC modulates sphingolipid levels and MCL-1 splicing to induce apoptosis in acute myeloid leukemia
Pearson, J. M., Tan, S. F., Sharma, A., Annageldiyev, C., Fox, T. E., Abad, J. L., Fabrias, G., Desai, D., Amin, S., Wang, H. G., Cabot, M. C., Claxton, D. F., Kester, M., Feith, D. J. & Loughran, T. P., 2020, In: Molecular Cancer Research. 18, 3, p. 352-363 12 p.Research output: Contribution to journal › Article › peer-review
6 Scopus citations -
Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia
Gebru, M. T., Atkinson, J. M., Young, M. M., Zhang, L., Tang, Z., Liu, Z., Lu, P., Dower, C. M., Chen, L., Annageldiyev, C., Sharma, A., Kawasawa, Y. I., Zhao, Z., Miller, B. A., Claxton, D. F. & Wang, H. G., Aug 27 2020, In: Blood. 136, 9, p. 1067-1079 13 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML
Zhao, C., Jia, B., Wang, M., Schell, T. D., Claxton, D. F., Ehmann, W. C., Rybka, W. B., Mineishi, S., Naik, S., Songdej, N., Sivik, J. M., Hohl, R. J., Zeng, H. & Zheng, H., Mar 1 2020, In: British Journal of Haematology. 188, 5, p. 674-684 11 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations